Latest Headlines

1. Twist Bioscience And IMIDomics Collaborate To Discover Antibodies For Applications In Immune-Mediated Inflammatory Diseases 9/27/2023

   Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and IMIDomics, Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced a multi-program collaboration whereby Twist will utilize its antigen development capabilities and Library of Libraries to conduct antibody discovery activities against targets identified by IMIDomics.

2. Viatris And Ocuphire Pharma Announce FDA Approval Of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops For The Treatment Of Pharmacologically-Induced Mydriasis Produced By Adrenergic Agonists Or Parasympatholytic Agents 9/27/2023

   Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents. RYZUMVl is expected to be commercially available in the U.S. in the first half of 2024.

3. Ono Enters Into A Drug Discovery Collaboration Agreement With Adimab To Discover Novel Antibody Drugs In The Oncology Field 9/27/2023

   Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration agreement with Adimab, LLC (Lebanon, New Hampshire, USA; CEO: Philip Chase; "Adimab"), the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, to discover and develop innovative antibody drugs in the oncology field.

4. Chrysalis Receives FDA Approval To Initiate Clinical Trials With Chrysalin (TP508) 9/26/2023

   Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure.

5. Phathom Pharmaceuticals Announces Vonoprazan NDA Submission For Non-Erosive GERD 9/26/2023

   Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the submission of an NDA to the FDA for vonoprazan as a daily treatment for Non-Erosive gastroesophageal reflux disease (GERD) in adults.

6. FDA Accepts Defender Pharmaceuticals’ New Drug Application For Intranasal Scopolamine Gel 9/26/2023

   Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) submission for intranasally administered scopolamine gel (DPI-386 Nasal Gel).

7. ABM Therapeutics' ABM-1310 Granted Fast Track Designation By The FDA Following Orphan Drug Designation 9/26/2023

   ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of ABM-1310 for the treatment of Glioblastoma (GBM) patients carrying BRAF V600E mutation, following the Orphan Drug Designation for ABM-1310 to treat malignant gliomas including GBM received in July.

8. Novo Nordisk And Evotec Collaborate To Launch LAB eN², A Translational Drug Discovery Accelerator, To Address Innovation Gap In Cardiometabolic Diseases 9/26/2023

   Novo Nordisk and Evotec SE, today announced LAB eN² (pronounced Lab ee – en – squared), a translational drug discovery accelerator that aims to nurture early research from academic institutions into novel therapeutics.

9. Pierre Fabre Laboratories And Vernalis Announce A Drug Discovery Collaboration In Oncology 9/25/2023

   Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets.

10. Drug Discovery On An Unprecedented Scale 9/22/2023

    Boosting virtual screening with machine learning allowed for a 10-fold time reduction in the processing of 1.56 billion drug-like molecules. Researchers from the University of Eastern Finland teamed up with industry and supercomputers to carry out one of the world’s largest virtual drug screens.